Cardioprotective efficiency study of combination of pyrimidine and 3-hydroxypyridine derivatives in experimental antitumor chemotherapy
Year: 2014, volume 10 Issue: №2 Pages: 257-261
Heading: Parmacology Article type: Original article
Authors: Siprov A.V., Kostina Yu.A.
Organization: Mordovia State University n.a. N. P. Ogaryov
Heading: Parmacology Article type: Original article
Authors: Siprov A.V., Kostina Yu.A.
Organization: Mordovia State University n.a. N. P. Ogaryov
Summary:
The aim of the study is to analyze the influence of combination of pyrimidine and 3-hydroxypyridine derivatives — xymedon and mexidol, in comparison with kardioxane on the myocardial bioelectric activity and arterial pressure level in rats with Walker-256 carcinoma at the doxorubicin and paclitaxel chemotherapy. Material and Methods. Experiments have been carried out on 100 Wistar female rats of weight of 150-250 grams. Doxorubicin and paclitaxel were administered intraperitoneally in a dosage of 4mg/kg and 6mg/kg respectively on the 11th day of experiment. Xymedon (100mg/kg) and mexidol (50mg/kg) were administered separately and in combination with each other, starting with the 11th day of experiment for 10 days. Kardioxane was injected in the dosage of 80mg/kg 20 min before cytostatics. We estimated a myocardial bioelectric activity and arterial pressure level changes on the 11th and 22d day of the experiment. The results. Xymedon and mexidol combination has limited the development of myocardial electrical instability comparable to kardioxane action. This combination has prevented the appearance of metabolic changes of ischemic genesis in the heart more efficiently than kardioxane. Xymedon and mexidol have normalized QT interval dispersion corrected by heart rate less efficiently than kardioxane. Conclusion. The combination of xymedon and mexidol has reduced cardiotoxicity of antitumor therapy more efficiently than the separated use of these medicines or the use of cardioxane.
Bibliography:
1. Jirkovsky E, Lencova-Popelova O, Hroch M, et al. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Toxicilogy 2013; (311): 191-204
2. Gershanovich ML. Kardioxane: anthracycline cardiotoxicity prevention. Voprosy onkologii 2004; 50 (4): 482-488
3. Semenova Al. Cardio- and neurotoxicity of antitumor medicines (pathogenesis, clinic, prevention, treatment). Practical oncology 2009; 10 (3): 168-176
4. Vershinina SF, Gershanovich ML, Makhnova EV, et al. Toxic effects of antitumor therapy on the cardiovascular system. Voprosy onkologii 2010; 56 (2): 234-239
5. Fandeev ОА, Vasechkin SS, Alekhin MN, et al. Clinical significance of anthracycline cardiotoxicity: modern approaches to diagnosis, prevention and treatment. Kardioligiia 2011; (7): 40-46
6. Octavia Y, Tocchetti CG, Gabrielson KL, et al. Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology 2012; (52): 1213-1225
7. Urakov AL. Cold in the heart protection. Nauka v SSSR 1987; (2): 63-65
8. Urakov AL. Prescription for temperature. Nauka I zhizn 1989; (9): 38-42
9. SiprovAV. Prospects of 3-hydroxypyridine derivatives as a remedies against anthracycline cardiotoxicity. Izvestiya vysshikh uchebnykh zavedeniy. Povolzhskiy region. Meditsinskie nauki 2006; (1): 58-64
10. Stolyarova VV. Correction of myocardial electric instability by medicines with antioxidant activity. Saransk, 2004; 100 p.
| Attachment | Size |
|---|---|
| 2014_02_257-261.pdf | 287.06 KB |
Русский
English